General Information of Drug (ID: DMUSOM9)

Drug Name
ABBV-CX-2029 Drug Info
Indication
Disease Entry ICD 11 Status REF
Hematologic tumour 2B33.Y Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMUSOM9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CX2029 DMYTTBK Aggressive cancer 2A00-2F9Z Phase 1/2 [2]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Transferrin receptor protein 1 (TFRC) TT8MG4S TFR1_HUMAN Not Available [1]

References

1 Clinical pipeline report, company report or official report of AbbVie.
2 Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug Conjugate. Mol Cancer Ther. 2022 Aug 2;21(8):1326-1336.